Abstract
The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.
| Translated title of the contribution | [Treatment of neuroendocrine tumours of the gastrointestinal tract] |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 172 |
| Issue number | 43 |
| Pages (from-to) | 2942-5 |
| Number of pages | 4 |
| Publication status | Published - 25 Oct 2010 |